Kalaris Therapeutics KLRS
NASDAQ KLRS
$1.75 -0.15 (-7.85%)
As of: Nov 12, 2026 · 1:06 PM EST

Kalaris Therapeutics (KLRS) Return on Invested Capital [ROIC] (2022 - 2023)

Updated

Analysis

Kalaris Therapeutics (KLRS) Return on Invested Capital [ROIC] (2022 - 2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROIC (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 30.89%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 17.57%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 24.28%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 2.52%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 23.11%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 15.60%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -6.11%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 12.34%
10 Kalaris Therapeutics 44.52 Mn -38.38 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 -228.97%
Sep 30, 2023 -79.59%
Jun 30, 2023 -79.04%
Dec 31, 2022 -70.22%
Sep 30, 2022 -89.80%
API Access

Kalaris Therapeutics Return on Invested Capital [ROIC] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-invested-capital-%5Broic%5D&ticker=KLRS&period=max&api_key=YOUR_API_KEY